Literature DB >> 32112184

Factors associated with positive outcomes of platelet-rich plasma therapy in Achilles tendinopathy.

Michele Abate1, Luigi Di Carlo2, Alberto Belluati3, Vincenzo Salini4.   

Abstract

BACKGROUND: The efficacy of platelet-rich plasma in the treatment for Achilles tendinopathy is debated. Therefore, it is important to know which factors, related to the subjects and/or the disease, are associated with positive or negative outcomes. Aim of this study was to evaluate in a large cohort of patients with Achilles mid-portion tendinopathy which variables were independently associated with a positive outcome after platelet-rich plasma treatment.
MATERIAL AND METHODS: Eighty-four subjects with Achilles tendinopathy were evaluated by means of VISA-A score and ultrasound and treated with a single platelet-rich plasma injection once a week for 3 weeks. Afterward, a rehabilitation program, based on eccentric training, was implemented. At 3 and 6 months, the relationship between the mean VISA-A score and the following putative predictors was evaluated: sex, age, physical activity, sport, smoking, metabolic risk factors, BMI, symptoms duration, tendon damage, neovessels, adherence to eccentric training. Finally, the percentage of clinically evident positive outcomes (defined as an increase in VISA-A score ≥ 20 points) related to each variable was computed.
RESULTS: At final follow-up, using the General Linear Model for Repeated Measures procedure, male sex (0.02), age ≤ 40 (0.05) and adequate eccentric training (0.02) were found to be independently associated with a significant increase in the mean VISA-A score. Moreover, the clinically evident positive outcomes, as previously defined, were significantly associated with male sex (0.01), age ≤ 40 (0.000), BMI ≤ 25 (0.001), symptoms duration ≤ 12 months (0.02) and good adherence to eccentric training (0.004).
CONCLUSION: Younger age, male sex and good adherence to eccentric training can be considered predictors of better results after platelet-rich plasma therapy in Achilles tendinopathy.

Entities:  

Keywords:  Achilles tendinopathy; Outcomes; Platelet-rich plasma; Ultrasound

Mesh:

Year:  2020        PMID: 32112184     DOI: 10.1007/s00590-020-02642-1

Source DB:  PubMed          Journal:  Eur J Orthop Surg Traumatol        ISSN: 1633-8065


  69 in total

1.  Chronic Achilles tendinosis: recommendations for treatment and prevention.

Authors:  H Alfredson; R Lorentzon
Journal:  Sports Med       Date:  2000-02       Impact factor: 11.136

2.  Age-related changes in focal adhesions lead to altered cell behavior in tendon fibroblasts.

Authors:  Solfrid M Arnesen; Moira A Lawson
Journal:  Mech Ageing Dev       Date:  2006-06-15       Impact factor: 5.432

3.  Platelet rich plasma compared to dry needling in the treatment of non-insertional Achilles tendinopathy.

Authors:  Michele Abate; Luigi Di Carlo; Vincenzo Salini
Journal:  Phys Sportsmed       Date:  2018-11-21       Impact factor: 2.241

4.  Interaction between testosterone and growth hormone on whole-body protein anabolism occurs in the liver.

Authors:  Vita Birzniece; Udo J Meinhardt; Margot A Umpleby; David J Handelsman; Ken K Y Ho
Journal:  J Clin Endocrinol Metab       Date:  2011-01-14       Impact factor: 5.958

5.  Sex-based difference in Achilles peritendinous levels of matrix metalloproteinases and growth factors after acute resistance exercise.

Authors:  Broc D Astill; Mark S Katsma; David J Cauthon; Jason Greenlee; Mark Murphy; Donald Curtis; Chad C Carroll
Journal:  J Appl Physiol (1985)       Date:  2016-11-23

6.  Heavy Slow Resistance Versus Eccentric Training as Treatment for Achilles Tendinopathy: A Randomized Controlled Trial.

Authors:  Rikke Beyer; Mads Kongsgaard; Birgitte Hougs Kjær; Tommy Øhlenschlæger; Michael Kjær; S Peter Magnusson
Journal:  Am J Sports Med       Date:  2015-05-27       Impact factor: 6.202

7.  Effect of growth hormone on aging connective tissue in muscle and tendon: gene expression, morphology, and function following immobilization and rehabilitation.

Authors:  A P Boesen; K Dideriksen; C Couppé; S P Magnusson; P Schjerling; M Boesen; P Aagaard; M Kjaer; H Langberg
Journal:  J Appl Physiol (1985)       Date:  2013-11-14

8.  Magnetic resonance and ultrasound in achilles tendinopathy: Predictive role and response assessment to platelet-rich plasma and adipose-derived stromal vascular fraction injection.

Authors:  Domenico Albano; Carmelo Messina; Federico Giuseppe Usuelli; Laura De Girolamo; Miriam Grassi; Camilla Maccario; Bianca Bignotti; Alberto Tagliafico; Luca Maria Sconfienza
Journal:  Eur J Radiol       Date:  2017-08-09       Impact factor: 3.528

9.  Impact of autologous blood injections in treatment of mid-portion Achilles tendinopathy: double blind randomised controlled trial.

Authors:  Kevin J Bell; Mark L Fulcher; David S Rowlands; Ngaire Kerse
Journal:  BMJ       Date:  2013-04-18

10.  Relationships of Age and Sex with Cytokine Content and Distribution in Human Platelet Fibrin Gels.

Authors:  Meng-Yi Bai; Meng-Han Chuang; Ming-Fang Lin; Sung-Ling Tang; Chin-Chean Wong; Wing P Chan
Journal:  Sci Rep       Date:  2018-07-13       Impact factor: 4.379

View more
  2 in total

1.  ICON 2020-International Scientific Tendinopathy Symposium Consensus: A Systematic Review of Outcome Measures Reported in Clinical Trials of Achilles Tendinopathy.

Authors:  Karin Grävare Silbernagel; Peter Malliaras; Robert-Jan de Vos; Shawn Hanlon; Mitchel Molenaar; Håkan Alfredson; Inge van den Akker-Scheek; Jarrod Antflick; Mathijs van Ark; Kenneth Färnqvist; Zubair Haleem; Jean-Francois Kaux; Paul Kirwan; Bhavesh Kumar; Trevor Lewis; Adrian Mallows; Lorenzo Masci; Dylan Morrissey; Myles Murphy; Richard Newsham-West; Richard Norris; Seth O'Neill; Koen Peers; Igor Sancho; Kayla Seymore; Patrick Vallance; Arco van der Vlist; Bill Vicenzino
Journal:  Sports Med       Date:  2021-11-19       Impact factor: 11.136

2.  Causal Associations of Obesity With Achilles Tendinopathy: A Two-Sample Mendelian Randomization Study.

Authors:  Lijuan He; Tingting Yu; Wei Zhang; Baojian Wang; Yufeng Ma; Sen Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-14       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.